Guenter Hoelzemann

USPTO Granted Patents = 30 (Patent Applications = 3)

CIPO Patents = 10 (Patent Applications = 2)

EPO Patents = 20 (Patent Applications = 18)

Average Co-Inventor Count = 4.3

ph-index = 6

Forward Citations = 82(Granted Patents)

Location History:

Seeheim-Jegenheim, DE (2014)
Seeheim-Jugenheim, DE (2007 - 2018)

Company Filing History:

Merck Patent Gesellschaft MIT Beschrankter Haftung

patents

2 out of 10

Biomet Deutschland Gmbh

patents

Years Active: 2007-2018

Loading Chart...

30 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 9861635 - Macrocycles as kinase inhibitors (2018-01-09),

2. 9855268 - Triazolo[4,5-d]pyrimidine derivatives (2018-01-02),

3. 9617266 - Imidazopyrimidine derivatives (2017-04-11),

4. 9409914 - Triazolo[4,5-d]pyrimidine derivatives (2016-08-09),

5. 9273029 - Pyridine-and pyrazine derivatives (2016-03-01),

6. 9102675 - 3-Cyanoaryl-1H-pyrrolo[2,3-B] pyridine derivatives (2015-08-11),

7. 9051318 - Pyrido [2, 3-B] pyrazine compounds and their therapeutical uses such as for inhibiting ATP consuming proteins and treating diseases associated therewith (2015-06-09),

8. 9051307 - Bipyridyl derivatives (2015-06-09),

9. 9045493 - Furo[3,2-b]- and thieno[3,2-b]pyridin derivatives (2015-06-02),

10. 8969335 - Benzonitrile derivatives as kinase inhibitors (2015-03-03),

11. 8912216 - Hetaryl-[1,8]naphthyridine derivatives (2014-12-16),

12. 8846931 - Bipyridyl derivatives (2014-09-30),

13. 8791113 - 2,4-diaryl-substituted [1,8] naphthyridines as kinase inhibitors for use against cancer (2014-07-29),

14. 8614226 - Hetaryl-[1,8]naphthyridine derivatives (2013-12-24),

15. 8389554 - Imidazothiadiazole derivatives (2013-03-05),

Title: **The Innovative Contributions of Guenter Hoelzemann**

Introduction

Guenter Hoelzemann, based in Seeheim-Jugenheim, Germany, is a prolific inventor with a remarkable portfolio that includes 30 patents. His work primarily focuses on the field of medicinal chemistry, with a strong emphasis on compounds that offer solutions for cancer treatment.

Latest Patents

Among his latest innovations, Hoelzemann has developed macrocycles as kinase inhibitors, encompassing compounds that specifically inhibit GCN2, a promising target for cancer therapies. Additionally, he has created triazolo[4,5-d]pyrimidine derivatives, which also serve as inhibitors of GCN2 and hold potential for treating cancer. These patents reflect his commitment to advancing medical science through innovative chemical solutions.

Career Highlights

Throughout his career, Guenter Hoelzemann has been associated with esteemed organizations, including Merck Patent GmbH and Merck Patent Gesellschaft mit beschränkter Haftung. His tenure at these companies has significantly shaped his expertise in patent law and the application of innovative technologies in pharmaceutical development.

Collaborations

Hoelzemann has also collaborated closely with notable colleagues such as Dieter Dorsch and Alfred Jonczyk. These partnerships have likely contributed to the success of his innovative endeavors, fostering an environment of shared knowledge and expertise in the ever-evolving landscape of drug development.

Conclusion

Guenter Hoelzemann stands out as a key inventor in the realm of medicinal chemistry, particularly in the fight against cancer through his unique compounds. With a successful career marked by numerous patents and valuable collaborations, his contributions continue to influence the fields of innovation and pharmaceutical research.

This text is generated by artificial intelligence and may not be accurate.